secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001628280-23-009629
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics reports 2022 net loss of $41.7M; Phase 2 PEAK trial enrollment complete
--------------------------------------------------------------------------------

- Net loss of $41.7M for 2022, improved from $84.4M in 2021; net loss per share $4.43.
- Total revenues $18.1M, up from $5.4M, driven by $14.5M upfront from AVTX-007 out-license.
- Cash and equivalents $13.2M at Dec 31, 2022; raised $13.7M net in Feb 2023 public offering.
- Completed enrollment of Phase 2 PEAK trial of AVTX-002 in non-eosinophilic asthma (91 patients); topline data expected Q2 2023.
- Identified lead molecule for AVTX-008 (BTLA agonist); target IND submission in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023009629/0001628280-23-009629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023009629/avtx-20230329.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-009629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer